In vitro and in vivo antitumor effect of gefitinib nanoparticles on human lung cancer

Gefitinib (GEF) is the first epidermal growth factor receptor (EGFR)-targeting agent launched as an anticancer drug. It is an accepted opinion that modifying GEF strong hydrophobicity and poor bioavailability would not only enhance its antitumor effects, but also reduce its side effects. In this stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Xiao Ling, Chen, Long Xia, Zhang, Heng, Yang, Bo, Xu, Shan, Wu, Min, Liu, Jing, Yang, Ling Lin, Chen, Yue, Fu, Shao Zhi, Wu, Jing Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241075/
https://www.ncbi.nlm.nih.gov/pubmed/28961023
http://dx.doi.org/10.1080/10717544.2017.1384862

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241075/
https://www.ncbi.nlm.nih.gov/pubmed/28961023
http://dx.doi.org/10.1080/10717544.2017.1384862

Ejemplares similares